Testing patterns, patient and tumour characteristics and survival by NRAS and KIT genotype in melanoma
Clinical and Experimental Dermatology · 2026
DOI: 10.1093/ced/llaf543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Khaylen Mistry und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Norfolk and Norwich University Hospitals Foundation Trust, Norwich, UK. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins c-kit, Membrane Proteins, GTP Phosphohydrolases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.
Abstract (Originalsprache)
Background
NRAS and KIT mutations in melanoma bring implications for prognosis, follow-up, selection into trials and potential future treatment with targeted therapies. The frequency of NRAS/KIT mutations and their association with patient/tumour characteristics and survival is poorly documented.
Objectives
To report national data from England on (i) the frequency of NRAS and KIT mutations, (ii) the association of patient/tumour characteristics with NRAS and KIT mutations, and (iii) the survival of patients with NRAS and KIT mutations.
Methods
This retrospective cohort study identified all new melanomas diagnosed in England from 2016 to 2021 and molecular NRAS/KIT testing using data from the National Disease Registration Service. Multivariate logistic regression determined the association between (i) NRAS and KIT testing and patient/tumour characteristics, and (ii) NRAS genotype and patient/tumour characteristics. Age-standardized net survival (NS) analysed melanoma-specific mortality by NRAS and KIT genotype.
Results
Of new melanomas diagnosed, 6.6% (6045/91 415) and 3.0% (2705/91 415) had an NRAS and KIT test registered. The proportion of successfully tested tumours that were NRAS and KIT mutated were 30.8% (1811/5887) and 5.8% (148/2560). East of England NRAS tested the highest proportion of cutaneous tumours (11.2%, 1114/9950) compared with the lowest in the North West (1.4%, 172/12 296). Older patients were more likely to have NRAS mutations [odds ratio (OR) 1.01, 95% confidence interval (CI) 1.01–1.02]. Women (OR 0.81, 95% CI 0.71–0.91) and those with head/neck melanomas (OR 0.37, 95% CI 0.31–0.44) were less likely to have NRAS mutations. There was no significant difference in 5-year NS between all-stage NRAS wildtype (WT) and mutated tumours (WT NS 62.3%, 95% CI 58.9–65.9 vs. mutated NS 58.5%, 95% CI 54.0–63.4). Similarly, there was no significant difference in 5-year NS between KIT WT and mutated tumours (WT NS 50.4%, 95% CI 44.7–57.3 vs. mutated NS 52.1%, 95% CI 37.1–73.2).
Conclusions
This is the largest national dataset on melanoma NRAS and KIT status published to date to the best of our knowledge. Variations in NRAS/KIT testing by geographic/demographic factors drive initiatives to ensure consistent care. NRAS-mutated melanoma had a high incidence, which emphasizes the unmet need to develop therapies and trials for NRAS-mutated melanoma. This study increases our understanding of biomarkers NRAS and KIT and provides a foundation for optimizing melanoma care, contributing to advancements in precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Norfolk and Norwich University Hospitals Foundation Trust, Norwich, UK.
- Norwich Medical School, University of East Anglia, Norwich, UK.
- National Disease Registration Service, NHS England, Leeds, UK.
- Department of Oncology, The Christie NHS Foundation Trust, Manchester, UK.
- University of Manchester, Manchester, UK.
- Norwich Epidemiology Centre, University of East Anglia, Norwich, UK.
ORCID-Profile: Khaylen Mistry, Nick J Levell, Dimitrios Karponis, Charlotte Proby
Förderung
- Cancer Research UK
Zitieren
APA
Mistry, K., Jeffrey, P., Levell, N. J., Kennedy, O., Richardson, K., Craig, P., Bright, C., Taylor, S., Ragan, J., Karponis, D., Pethick, J., Lavelle, K., McRonald, F., Hardy, S., Vernon, S., Dawe, R., Proby, C., Lorigan, P., & Venables, Z. C. (2026). Testing patterns, patient and tumour characteristics and survival by NRAS and KIT genotype in melanoma. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf543
Vancouver
Mistry K, Jeffrey P, Levell NJ, Kennedy O, Richardson K, Craig P, et al. Testing patterns, patient and tumour characteristics and survival by NRAS and KIT genotype in melanoma. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llaf543
BibTeX
@article{Mistry2026,
author = {Mistry, Khaylen and Jeffrey, Polly and Levell, Nick J and Kennedy, Oliver and Richardson, Kathryn and Craig, Paul and Bright, Chloe and Taylor, Siobhan and Ragan, John and Karponis, Dimitrios and Pethick, Joanna and Lavelle, Katrina and McRonald, Fiona and Hardy, Steven and Vernon, Sally and Dawe, Robert and Proby, Charlotte and Lorigan, Paul and Venables, Zoe C},
title = {Testing patterns, patient and tumour characteristics and survival by NRAS and KIT genotype in melanoma},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llaf543}
}
EUVIMED